#USA #Barcelona #Clinical Trials #Indero #Veeva RTSM

Indero Celebrates 40th RTSM Study Launch

In a remarkable achievement, Indero, a leading clinical research organization previously known as Innovaderm Research, has successfully executed its 40th RTSM (Randomization and Trial Supply Management) study using Veeva RTSM. This milestone reflects Indero's commitment to enhancing operational efficiency and expediting clinical trial timelines.

A Strategic Partnership

The adoption of Veeva RTSM has been a game-changer for Indero. By standardizing their operations with this sophisticated software, the company has vastly improved the performance of its clinical trials. Eric Hardy, the senior director of biometrics at Indero, expressed that the integration of Veeva RTSM has enabled the organization to boost efficiency and foster closer collaboration amongst teams, ensuring smoother execution processes.

As Hardy states, "By optimizing our clinical trial operations, Veeva RTSM has led to more efficient processes and closer collaboration to ensure smooth executions." This increased speed and efficiency allow Indero to accelerate the time it takes to bring therapies to market, significantly benefiting sponsors, study sites, and patients.

Advancements in Clinical Trials

The launch of the 40th RTSM study signifies more than just a number; it represents the ongoing collaboration between Indero and Veeva. Since the initial implementation of Veeva RTSM, Indero has worked closely with Veeva to continuously refine and standardize processes that are crucial for the long-term success of their clinical trials.

Steve Simmerman, the General Manager of Veeva RTSM, commented on this partnership: "With its enterprise RTSM approach, Indero is achieving greater efficiency and long-term reliability in its studies." This collaboration not only speeds up study timelines but also showcases an optimized approach that can significantly impact the industry.

Looking Ahead

As Indero continues to build on its successful implementations, the role of technology in clinical trials remains pivotal. The integration of advanced solutions like Veeva RTSM positions organizations like Indero to meet the growing demands of the healthcare sector more effectively. With the capability to improve processes and outcomes, the potential for innovation in clinical research appears endless.

Indero's successful execution of its 40th RTSM study reinforces the importance of embracing new technologies in the field of clinical trials. The future looks promising as Indero and Veeva pave the way for more efficient and effective clinical research and ultimately improve patient outcomes.

For more information about Veeva's RTSM solutions and their impact on clinical trials, visit Veeva.